Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With F2-F4 Fibrosis: a Randomized, Double-blind Placebo-controlled Trial

NCT05147090 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT05147090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05147090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With F2-F4 Fibrosis: a Randomized, Double-blind Placebo-controlled Trial
Lead sponsor
The University of Hong Kong
Phase
Phase 4
Overall status
Active, not recruiting
Start date
January 2, 2022
Completion date
December 31, 2027
Enrollment
106 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b, cirrhosis, empagliflozin, fibrosis, liver, nafld, sglt2 inhibitors